(NASDAQ: ATHA) Athira Pharma's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 43.47%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 42.48%.
Athira Pharma's earnings in 2025 is -$37,723,000.On average, 4 Wall Street analysts forecast ATHA's earnings for 2025 to be -$26,107,743, with the lowest ATHA earnings forecast at -$25,083,910, and the highest ATHA earnings forecast at -$26,875,618. On average, 4 Wall Street analysts forecast ATHA's earnings for 2026 to be -$19,470,181, with the lowest ATHA earnings forecast at -$20,020,748, and the highest ATHA earnings forecast at -$18,634,866.
In 2027, ATHA is forecast to generate -$804,553 in earnings, with the lowest earnings forecast at -$773,002 and the highest earnings forecast at -$828,216.